Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 13/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16239054 | 0.84 | MAPT (0.52) | MAPTMEN1KMT2AHSD17B10ALOX15 | |
| SCHEMBL14972509 | 0.79 | P2RX4 (0.55) | MAPTMEN1KMT2AP2RX4RAB9A | |
| SCHEMBL16239093 | 0.77 | P2RX4 (0.67) | P2RX4 | |
| SCHEMBL16239039 | 0.77 | MAPT (0.56) | MAPTMEN1KMT2AHSD17B10P2RX4 | |
| SCHEMBL30094440 | 0.77 | P2RX4 (0.67) | P2RX4 | |
| SCHEMBL16239507 | 0.76 | P2RX4 (0.44) | MAPTMEN1KMT2AP2RX4 | |
| SCHEMBL16267449 | 0.73 | P2RX4 (0.54) | MAPTMEN1KMT2AP2RX4RAB9A | |
| SCHEMBL30094520 | 0.73 | P2RX4 (0.51) | P2RX4 | |
| SCHEMBL16239195 | 0.73 | P2RX4 (0.51) | P2RX4 | |
| SCHEMBL16239478 | 0.73 | P2RX4 (0.51) | P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-12-19 | — | — | US | disclosed |
| US-12116351-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-10-15 | — | — | US | disclosed |
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-12-01 | — | — | US | disclosed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | disclosed |
| CN-108863959-B | P2X4 receptor antagonists | 日本化学药品株式会社 | 2021-11-30 | — | — | CN | disclosed |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-07-16 | — | — | US | disclosed |
| CN-111333588-A | P2X4 receptor antagonists | 日本化学药品株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-10633349-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-04-28 | — | — | US | disclosed |
| US-20180201587-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2018-07-19 | — | — | US | disclosed |
| US-9969700-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD. (JP) | 2018-05-15 | — | — | US | disclosed |
| EP-2803662-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160280667-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-09-29 | — | — | US | disclosed |
| US-9382236-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-07-05 | — | — | US | disclosed |
| US-20140357858-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2014-12-04 | — | — | US | disclosed |
| EP-2803662-A1 | P2X4 RECEPTOR ANTAGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2014-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | MAPT 4724/4885MEN1 3450/4885KMT2A 2174/4885 |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | MAPT 4732/4885MEN1 3285/4885KMT2A 2558/4885 |
| US-12116351-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | MAPT 4724/4885MEN1 3450/4885KMT2A 2174/4885 |
| US-20160280667-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | MAPT 4720/4885MEN1 3353/4885KMT2A 2156/4885 |
| US-20140357858-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | MAPT 4724/4885MEN1 3450/4885KMT2A 2174/4885 |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | MAPT 4724/4885MEN1 3450/4885KMT2A 2174/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | MAPT 4724/4885MEN1 3450/4885KMT2A 2174/4885 |
| US-10633349-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | MAPT 4724/4885MEN1 3450/4885KMT2A 2174/4885 |
| US-20180201587-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | MAPT 4724/4885MEN1 3450/4885KMT2A 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.